Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,840.00+1.10%ETH$2,504.38+3.44%GOLD$4,420.40+0.30%OIL$99.44-2.97%
Smart Investors Daily
YD

NASDAQ · YDES

YD Bio Limited Ordinary Shares

Healthcare · Biotechnology

$3.90

Down-$0.03 (-0.64%)

Updated Sep 11, 2026, 12:02 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
894.92M
P/E ratio
-14.54
Dividend yield
0.00%
52-week range
$1.70 – $8.77
Volume
633.43K
Avg. volume
92.84K

Price performance

YDES price history

1M range · 20 trading sessions · Daily adjusted prices

YDES closed at $3.90 after 20 trading sessions, up 55.38% for the selected period.

Last close
$3.90
Period change
+55.38%
Period low
$2.51
Period high
$4.80
Daily close
View OHLC price history
YDES OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$3.82$4.3097$3.7289$3.90633.43K
Sep 9, 2026$4.36$4.38$3.65$3.925730.63K
Sep 8, 2026$3.72$4.4999$3.65$4.25503.3K
Sep 4, 2026$3.67$3.88$3.29$3.54687.09K
Sep 3, 2026$3.64$4.05$3.21$3.67672.07K
Sep 2, 2026$3.71$4.015$3.50$3.76567.67K
Sep 1, 2026$3.77$4.08$3.36$3.775428.67K
Aug 31, 2026$4.87$4.87$3.10$3.71445.43K
Aug 28, 2026$3.94$4.80$3.09$4.80217.85K
Aug 27, 2026$4.34$4.34$3.80$3.8727.05K
Aug 26, 2026$4.85$4.85$4.00$4.3411.37K
Aug 25, 2026$4.75$4.77$4.097$4.689.66K
Aug 24, 2026$4.66$4.767$4.455$4.6618.54K
Aug 21, 2026$4.56$5.00$4.40$4.6936.01K
Aug 20, 2026$4.39$4.99$4.0091$4.7858105.12K
Aug 19, 2026$3.94$4.55$3.6001$4.4783.94K
Aug 18, 2026$3.50$4.00$3.38$3.9887.78K
Aug 17, 2026$3.11$3.40$2.79$3.3764.6K
Aug 14, 2026$2.76$3.2399$2.415$2.9873.61K
Aug 13, 2026$2.69$2.77$2.39$2.5116.31K

Latest YDES news

The latest Smart Investors Daily articles mentioning YDES.

Stock researchCompany · Overview

YDES research

Overview

Company profile and research snapshot.

Company profile

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 31, 2026

YD Bio Limited Reports Unaudited Financial Results for the Six Months Ended June 30, 2026

TAIPEI, Taiwan, Aug. 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation–based cancer detection technology and ophthalmologic innovations, today announced its financial results for the six months ended June 30, 2026. Management Commentary“The first half of 2026 marks a historic turning point for YD Bio, highlighted by our transition to bottom-line profitability and a remarkable 315% surge in top-line revenue,”

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By